bosutinib
5
Bosutinib
-
Upload
abeer-ahmed -
Category
Health & Medicine
-
view
38 -
download
0
Transcript of bosutinib
Bosutinib
Bosutinib received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March 2013 re-spectively.
bosutinib is a tyrosine kinase inhibitor for use in the treat-ment of chronic myelogenous leukemia (CML).
Bosutinib suppresses migra-tion and invasion of human breast cancer cells as it in-hibits signaling pathways in-volved in controlling tumor cell motility and invasion
Bosutinib forms:
• Bosulif 100 mg.• Bosulif 500 mg.
bosutinib structure:
Mechanism of action :
